Among fully vaccinated, study shows Paxlovid does not shorten symptoms | CIDRAP
A new study in the New England Journal of Medicine suggests that, for those fully vaccinated against COVID-19 but having at least one risk factor for severe COVID, the antiviral drug Paxlovid did little to reduce symptom duration, but experts caution the findings might not apply to older patients.| CIDRAP
